^
    4ms
    CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma. (PubMed, Biomol Biomed)
    Additionally, a high level of CTHRC1 was correlated with decreased sensitivity to antitumor drugs (vemurafenib, PLX-4720, dabrafenib, and SB-590885) targeting the BRAF(V600E) mutation. This study provides evidence of a significant correlation between CTHRC1 and the BRAF(V600E) mutation, suggesting its potential utility as a diagnostic and prognostic biomarker in human colon cancer, thyroid cancer, and melanoma.
    Journal • IO biomarker • Immune cell
    |
    BRAF (B-raf proto-oncogene)
    |
    Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • PLX4720 • SB-590885
    over1year
    Pan-Cancer Analysis of the TRP Family, Especially TRPV4 and TRPC4, and Its Expression Correlated with Prognosis, Tumor Microenvironment, and Treatment Sensitivity. (PubMed, Biomolecules)
    Our study elucidated the possible role of TRP family genes in cancer progression and provided insights for further studies on TRP family genes as potential pan-cancer targets to develop diagnostic and therapeutic strategies.
    Journal • IO biomarker • Pan tumor
    |
    TRPC4 (Transient Receptor Potential Cation Channel Subfamily C Member 4)
    |
    PLX4720 • SB-590885
    2years
    Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer. (PubMed, Front Pharmacol)
    Finally, we proposed 16 candidate repurposing drugs YM201636, masitinib, SB590885, GSK1070916, GSK2126458, ZSTK474, dasatinib, fedratinib, dabrafenib, methotrexate, trametinib, tubastatin A, BIX02189, CP466722, afatinib, and belinostat for BC through molecular docking analysis. Using BC cell lines, we validated that masitinib inhibits the mTOR signaling pathway and induces apoptotic cell death. Therefore, the proposed results might play an effective role in the treatment of BC patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TOP2A (DNA topoisomerase 2-alpha) • BIRC5 (Baculoviral IAP repeat containing 5) • AURKA (Aurora kinase A) • SOX2 • MIR34A (MicroRNA 34a-5p) • TP63 (Tumor protein 63) • CDK1 (Cyclin-dependent kinase 1) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • KDM5B (Lysine Demethylase 5B)
    |
    Mekinist (trametinib) • Gilotrif (afatinib) • dasatinib • Tafinlar (dabrafenib) • methotrexate • omipalisib (GSK2126458) • Beleodaq (belinostat) • Inrebic (fedratinib) • NMI-900 • OP-11 • SB-590885 • Kinaction (masitinib)
    almost3years
    A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies. (PubMed, Cancer Med)
    The BRAF signature may better help guide targeted therapy for melanoma, and such a framework can be applied to other cancers and mutations to provide more information than mutation status alone.
    Journal • Gene Signature
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • EGFR amplification • RAF1 amplification
    |
    PLX4720 • SB-590885